KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Accured Expenses (2016 - 2025)

NovoCure's Change in Accured Expenses history spans 12 years, with the latest figure at $18.5 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 3.01% year-over-year to $18.5 million; the TTM value through Dec 2025 reached $4.9 million, down 74.1%, while the annual FY2025 figure was $4.9 million, 74.1% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $18.5 million at NovoCure, up from $789000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $19.0 million in Q4 2024 and bottomed at -$16.4 million in Q1 2025.
  • The 5-year median for Change in Accured Expenses is $789000.0 (2025), against an average of $3.0 million.
  • The largest YoY upside for Change in Accured Expenses was 703.72% in 2025 against a maximum downside of 1112.33% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$10.7 million in 2021, then skyrocketed by 191.59% to $9.8 million in 2022, then skyrocketed by 92.17% to $18.9 million in 2023, then grew by 0.98% to $19.0 million in 2024, then decreased by 3.01% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Change in Accured Expenses are $18.5 million (Q4 2025), $789000.0 (Q3 2025), and $2.1 million (Q2 2025).